CHF6297 (CHF-6297) is a potent and selective p38α/β MAPK inhibitor with IC50 of 0.14/0.2 nM, >1,000-fold selectivity against p38γ and p38δ.
CHF6297 inhibits IL-8 release evoked by CSE in HBSMCs with IC50 of 0.79 nM.
CHF6297 dose-dependently counteractes the IL-1β (0.3 mg/kg)-induced neutrophil influx (ED50 = 0.22 mg/kg) and increase in IL-6 levels (ED50 = 0.82 mg/kg) in the BALF of rats.
CHF6297 (0.1 mg/kg, i.n.) significantly decreases airway neutrophilia in murine house dust mite (HDM) model of asthma exacerbated by influenza virus A (IAV) (H3N3).
CHF6297 effectively counteracteds lung inflammation in experimental models.
